← All trials
NCT02315443
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2015
- Primary completion
- Mar 1, 2019
- Completion date
- May 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 558
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- NoNO Inc.Lead sponsor
- University of CalgaryCollaborator
- Dalhousie UniversityCollaborator
- University of TorontoCollaborator
- University of British ColumbiaCollaborator
- University of British ColumbiaOverall official - principal investigator
- University of TorontoOverall official - principal investigator
- Brain CanadaCollaborator
- Djavad Mowafaghian Centre for Brain HealthCollaborator
- Canadian Stroke NetworkCollaborator
- Trillium Health PartnersCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.